Sanofi, Lead Pharma join to develop drugs for autoimmune diseases
Sanofi and Lead Pharma agreed to collaborate in the discovery, development and marketing of the latter's lead drug candidates intended to treat a wide variety of autoimmune conditions, including inflammatory bowel disease and rheumatoid arthritis. The collaboration will focus on drugs that target the ROR gamma(t) nuclear hormone receptors. The partners did not reveal the value of the deal, but Lead said it will get an upfront fee, milestone payments and sales royalties from Sanofi. PharmaTimes (U.K.)
(2/18), Genetic Engineering & Biotechnology News
|5 tips for managing negative online comments|
The Internet gives your customers a voice online, but what can you do when that voice is yelling negative comments? With 5 tips, you can learn how to positively respond and help direct the conversation. Read the article and learn the 5 ways to respond positively.
Takeda signs GI-drug-development pact with U.K. university
Takeda Pharmaceutical and Queen Mary University of London agreed to collaborate in the research and development of new drugs for gastrointestinal disorders. Gastrointestinal sensory and motor mechanisms related to motility and functional bowel disorders will be the focus of the collaboration. Under the agreement, Takeda's GI drug discovery unit will work on several areas of research with neurogastroenterology and immunology experts from Queen Mary. Pharmaceutical Business Review Online
Report: Minimally invasive surgical tools market to reach $14.13B by 2019
A MarketsandMarkets report predicts the market for minimally invasive surgical instruments will grow to $14.13 billion by 2019. The report cited the lower cost of care from minimally invasive surgeries, the superiority of these procedures over conventional open surgeries and the growing number of surgeries among the elderly as major factors expected to drive growth. BeckersSpine.com
Please contact one of our specialists for advertising opportunities,
editorial inquiries, job placements, or any other questions.